Search Results: "infuse"
-
BioNTech Pact and Stock Sale Infuse Autolus With $600M for Its Cell Therapies
Autolus will apply the capital to its CAR T-cell therapy currently under FDA review in cancer and in early clinical development in lupus. Meanwhile, BioNTech will gain access to Autolus’s cell therapy manufacturing assets as well as technologies that could support the R&D of in vivo therapies and antibody drug conjugates.
-
With FDA nod, ChemoCentryx pill stands out in a sea of injectable & infused meds
ChemoCentryx has spent decades developing oral alternatives to injectable and infused biologic drugs that treat chronic autoimmune conditions. The research finally paid off with FDA approval of Tavneos, a ChemoCentryx pill for a rare autoimmune disease.
-
Amicus deal puts it on path to profitability, infuses its gene therapies with $400M
Amicus Therapeutics is spinning its gene therapy pipeline into a separate entity that will go public via a SPAC merger. Executives say the transaction puts Amicus on a path to profitability while simultaneously securing the cash needed to develop the gene therapy assets.
-
Vertex, CRISPR Therapeutics infuse first patient in CRISPR/Cas9-based gene therapy study
The Phase I/II trial is in beta-thalassemia, a rare blood disorder. Another Phase I/II study of the same drug, in sickle cell disease, is expected to infuse its first patient in mid-2019.
-
Private equity firm Cerberus infuses $105M into vaccine maker PaxVax
PaxVax will use the funding to pay off its debts, as well as launch a cholera vaccien called Vaxchora.
-
Case against Medtronic’s Infuse bone-growth device now potentially headed to the Supreme Court
Years of pain and surgeries have led Patricia Caplinger to move things forward to the Supreme Court with her case against Medtronic and its Infuse device.
-
A 3D printed, keratin-infused burn dressing: North Carolina startup gets $1.7M
Keratins are an important class of proteins that help the body’s natural healing process – […]
-
Devices & Diagnostics, Hospitals
Medtronic is on the defensive again with InFuse. Will the Yale review redeem it?
Medtronic (NYSE:MDT) is once again on the defensive regarding its controversial bone graft product InFuse […]
-
DOJ closes investigation of Medtronic’s controversial product Infuse
In a short news release issued Wednesday afternoon, Medtronic (NYSE:MDT) disclosed that the U.S. Department of Justice […]
-
Medtronic to pay $85M to settle Infuse-related class action lawsuit
Medtronic (NYSE:MDT) announced Friday that it will pay $85 million to settle a class action […]
-
Infuse EU competitor working toward U.S. clearance for bone growth putty
Yet another company that’s hungry for some of Medtronic Infuse’s shrinking slice of the bone […]
-
Bear blood peptide to chase Medtronic’s Infuse market for bone growth
The race to substitute Medtronic’s Infuse bone growth product has a new contender in the […]
-
Who can win the race to substitute Medtronic’s Infuse bone graft product?
On Wednesday, I forwarded the argument of an analyst that Medtronic’s (NYSE:MDT) controversial bone graft product Infuse will likely live on in a diminished form, even if an independent review confirms its safety.
So the obvious question is, who will fill the void left by Infuse?
-
What is the future of Medtronic’s controversial spinal fusion product Infuse?
Medtronic’s controversial bone growth product Infuse has been hammered by quarter after quarter of declining […]